To ensure that our original findings were not erroneous and indeed represented the actual frequency found in bladder and kidney cancer patients, we re-evaluated the frequency of the NOD2 c.3020insC allele and the p.A148T polymorphism in CDKN2A among 706 bladder cancer and 410 kidney cancer patients. This evidence concerns the gene NOD2 and urinary bladder cancer.